Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359179 | 0.95 | ELANE (0.83) | ELANE | |
| Alvelestat SCHEMBL29989873 | 0.92 | ELANE (0.91) | ELANE | |
| Alvelestat SCHEMBL3021295 | 0.92 | ELANE (0.91) | ELANE | |
| Alvelestat SCHEMBL29740084 | 0.87 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL560757 | 0.87 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL29519811 | 0.87 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL30179302 | 0.87 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL3024664 | 0.85 | ELANE (0.85) | ELANE | |
| SCHEMBL4126035 | 0.80 | ELANE (0.74) | ELANE | |
| SCHEMBL560680 | 0.79 | ELANE (0.74) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4106757-B1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | MEREO BIOPHARMA 4 LTD (GB) | 2023-08-23 | — | — | EP | disclosed |
| CN-102405219-B | Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of COPD | ASTRAZENECA AB | 2013-11-06 | — | — | CN | disclosed |
| CN-102405219-A | Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of copd | ASTRAZENECA AB | 2012-04-04 | — | — | CN | disclosed |
| EP-2398792-A1 | TOSYLATE SALT OF A 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE, USEFUL IN THE TREATMENT OF COPD | AstraZeneca AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094964-A1 | TOSYLATE SALT OF A 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE, USEFUL IN THE TREATMENT OF COPD | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | WO | disclosed |